(Q33380054)

26 July 2017

1 reference

title

Bortezomib: a novel chemotherapeutic agent for hematologic malignancies (English)

1 reference

26 July 2017

1 reference

Kyle N Utecht

1

1 reference

PubMed ID

18574011

26 July 2017

Jill Kolesar

series ordinal

2

1 reference

26 July 2017

1 July 2008

1 reference

American Journal of Health-System Pharmacy

26 July 2017

1 reference

26 July 2017

65

1 reference

26 July 2017

13

1 reference

26 July 2017

1221-1231

1 reference

Multiple myeloma: diagnosis and treatment

26 July 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

31 March 2020

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Ubiquitin domain proteins in disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

The ubiquitin-proteasome system and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Bortezomib in the treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

An essential role for NF-kappaB in preventing TNF-alpha-induced cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Suppression of TNF-alpha-induced apoptosis by NF-kappaB

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Approval summary for bortezomib for injection in the treatment of multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

A phase 2 study of bortezomib in relapsed, refractory myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

An update: health economics of managing multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

Bortezomib in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070272

31 March 2020

Identifiers

DOI

10.2146/AJHP070272

1 reference

26 July 2017

1 reference

PubMed ID

18574011